U.S. adults: 1 in 8 on GLP‑1s

GLP-1 drugs are no longer a niche obesity story. They are turning into a mass-market American medicine story — big enough that “one in eight adults” now means current users, not just people who have ever tried them. That shift showed up in KFF’s November 14, 2025 poll, which put current use at 12% of U.S. adults, up from 6% in KFF’s May 2024 poll. The stakes are obvious: these drugs can move weight by double-digit percentages, but they are expensive, often long-term, and still unevenly covered. ### Where does the “1 in 8” come from? It comes from KFF, and the important detail is the date. In May 2024, KFF found that 12% of adults had ever taken a GLP-1 and 6% were currently taking one. By November 2025, KFF’s follow-up poll found 18% had ever taken one and 12% were currently taking one. So the viral claim is directionally right now, but it would have been wrong if you were using the older 2024 poll. (kff.org) ### Why did use jump so fast? Because the efficacy is unusually strong for a drug. In the STEP 1 trial, weekly semaglutide 2.4 mg produced an average 14.9% body-weight reduction at 68 weeks. In SURMOUNT-1, tirzepatide hit 20.9% at the 15 mg dose by week 72. Basically, these are numbers that used to make people think about surgery, not a weekly injection. (kff.org) ### Are people mostly taking them just to lose weight? Not entirely. In the 2024 KFF poll, many users said they were taking GLP-1s for diabetes, heart disease, or another chronic condition, and a smaller but still large share said weight loss was the sole reason. That matters because access often rides on diagnosis. The same drug can be easier to get when it is coded for diabetes than when it is prescribed for obesity alone. (nejm.org) ### So is supply still the main bottleneck? Less than before. FDA said tirzepatide supply had stabilized and clarified its compounding policy on April 1, 2026 after previously determining the tirzepatide injection shortage was resolved. That does not mean every pharmacy always has every dose, but it does mean the story is shifting from pure shortage toward cost, insurance rules, and who gets covered. (kff.org) ### What’s the catch once people start? The catch is that many people do not stay on therapy. Real-world discontinuation estimates run around 50% to 75% at 12 months, and a large cohort study found 46.5% of patients with type 2 diabetes and 64.8% without diabetes discontinued within a year. That is partly cost, partly side effects, partly the reality that long-term treatment is hard. (fda.gov) ### What happens if they stop? Usually, weight comes back. Trials of semaglutide and tirzepatide withdrawal show substantial regain after treatment stops. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% during the following year, while those who stayed on drug kept losing more. Think of these drugs less like a one-time reset and more like blood-pressure medicine — they work best while you keep taking them. (jamanetwork.com) ### Is insurance catching up? Only partly. KFF notes that Medicare has historically been barred from covering drugs used solely for obesity, though CMS is now rolling out a temporary Medicare GLP-1 Bridge starting in July 2026 and extending through 2027. Medicaid and employer coverage are still patchy, and affordability remains a top complaint even among insured users. (jamanetwork.com) ### Why does this matter beyond medicine? Because once 12% of adults are current users, GLP-1s stop being just a pharma story. They start touching grocery demand, employer benefits, Medicare budgets, and the politics of who deserves treatment for obesity. The big change is not just that the drugs work. It is that enough Americans are now on them for the whole system to have to adapt. (kff.org) The bottom line is simple: the “1 in 8” claim is now grounded in a newer KFF poll, not the older one people first shared. But the real story is bigger — blockbuster efficacy has created blockbuster demand, and the next fight is over who can stay on these drugs long enough to benefit. (kff.org 1) (kff.org 2)